Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.19.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Operating activities    
Net loss $ (17,693,601) $ (34,493,895)
Adjustments to reconcile net loss provided by (used in) operating activities:    
Depreciation and amortization 3,266,313 3,333,416
Impairment of intangible assets 1,449,121 1,861,562
Stock-based compensation 1,942,196 1,796,387
Acquired in-process research and development, including transaction costs 0 18,723,952
Deferred taxes 28,823 (47,994)
Amortization of inventory fair value associated with acquisition of TRx and Avadel's pediatric products 107,272 262,419
Non-cash interest expense 0 327,224
Change in fair value of warrant liability and unit purchase option liability (6,823) 22,328
Change in fair value of contingent consideration (1,009,168) 360,850
Changes in assets and liabilities:    
Accounts receivable, net (1,798,216) (73,513)
Other receivables 5,260,807 (3,072,729)
Inventory, net 601,241 (226,735)
Prepaid expenses and other assets (140,503) 27,571
Escrowed cash receivable 0 3,752,390
Accounts payable (619,669) 172,243
Income taxes payable (1,017,804) (64,100)
Accrued expenses and other liabilities (6,573,918) 6,186,178
License obligations (1,250,000) 0
Net cash used in operating activities (17,453,929) (1,152,446)
Investing activities    
Acquisition of Avadel's pediatric products 0 (1)
Cash acquired from the acquisition of Ichorion Therapeutics, Inc. 0 1,429,876
Purchase of property and equipment (262,011) (65,057)
Net cash (used in) provided by investing activities (262,011) 1,364,818
Financing activities    
Proceeds from exercise of stock options and warrants 257,993 508,746
Proceeds from sales of common stock under employee stock purchase plan 127,537 8,400
Restricted stock units withheld for taxes (33,959) 0
Proceeds from sale of shares pursuant to private placement, net 3,737,400 3,857,106
Proceeds from underwritten public offering, net 8,975,960 0
Payment of contingent consideration (567,911) (137,008)
Payment of long-term debt (73,026) 0
Net cash provided by financing activities 12,423,994 4,237,244
(Decrease) increase in cash, cash equivalents and restricted cash (5,291,946) 4,449,616
Cash, cash equivalents, and restricted cash at beginning of period 10,746,756 2,605,499
Cash, cash equivalents, and restricted cash at end of period 5,454,810 7,055,115
Supplemental disclosures of cash flow information    
Cash paid for interest 787,500 262,500
Cash paid for taxes 1,326,025 0
Supplemental disclosures of non-cash activities    
Leased asset obtained in exchange for new operating lease liability 743,025  
Debt assumed in Avadel Pediatric Products acquisition 0 (15,075,000)
Cash and cash equivalents 5,250,651 6,838,353
Restricted cash, current 102,214 37,027
Restricted cash, non-current $ 101,945 $ 179,735